Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
5don MSN
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
11hon MSN
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback